MedPath

Study Comparing 2 Different Formulations of Pantoprazole in Healthy Adults.

Phase 1
Completed
Conditions
Healthy Subjects
Registration Number
NCT00383916
Lead Sponsor
Wyeth is now a wholly owned subsidiary of Pfizer
Brief Summary

A study comparing 2 different investigational formulations of pantoprazole in healthy adults.

Detailed Description

open-label, single-dose, randomized, 2-period, 2-sequence, crossover, inpatient bioequivalence study

Recruitment & Eligibility

Status
COMPLETED
Sex
All
Target Recruitment
Not specified
Inclusion Criteria

Not provided

Exclusion Criteria

Not provided

Study & Design

Study Type
INTERVENTIONAL
Study Design
CROSSOVER
Primary Outcome Measures
NameTimeMethod
To determine the bioequivalence of the Altana formulation of pantoprazole to the Wyeth formulation of pantoprazole delayed-release granules.
Secondary Outcome Measures
NameTimeMethod
To obtain additional safety and tolerability data concerning pantoprazole in healthy subjects and to assess the pharmacokinetics of the Altana formulation.

MedPath

Empowering clinical research with data-driven insights and AI-powered tools.

© 2025 MedPath, Inc. All rights reserved.